Associated Papers
Multiple Endocrine Neoplasia Type 5 due to Germline MAX Mutations: A Systematic Review of Tumor Spectrum and Clinical Features.
Charoenngam N et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2025
Mutations to transcription factor MAX allosterically increase DNA selectivity by altering folding and binding pathways.
Hastings R et al.
Nature Communications, 2025
Unlocking the Genetic Secrets of Acromegaly: Exploring the Role of Genetics in a Rare Disorder.
Balinisteanu I et al.
Current Issues in Molecular Biology, 2024
Updates on the genetics of multiple endocrine neoplasia.
Sahakian N et al.
Annales D'endocrinologie, 2024
Genotype and clinical phenotype characteristics of MAX germline mutation-associated pheochromocytoma/paraganglioma syndrome.
Lian B et al.
Frontiers in Endocrinology, 2024
Bilateral Pheochromocytoma with Germline MAX Variant without Family History.
Hata S et al.
Clinics and Practice, 2022
35645312 (PubMed )
Supplement: clinpract-12-00035-s001.zip › clinpract-1702561-supplementary.pdf
Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?
Seabrook AJ et al.
The Journal of Clinical Endocrinology and Metabolism, 2021
Familial Acromegaly and Bilateral Asynchronous Pheochromocytomas in a Female Patient With a MAX Mutation: A Case Report.
Mamedova E et al.
Frontiers in Endocrinology, 2021
Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours.
Flynn A et al.
The Journal of Pathology, 2017
Select a paper to view details